Search research articles
Contact Us
Filters
Showing results (61-70 of 110) with videos related to
Page
of 11
Sort By:
Multiple Sclerosis and Related Disorders
|
November 23, 2015
Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure
Alicia S Chua, Bonnie I Glanz, Anthony J Guarino, et al.
Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology
|
December 17, 2016
Preliminary Predictors of Initial Attendance, Symptom Burden, and Motor Subtype in a US Functional Neurological Disorders Clinic Population
David L Perez, Sigrid S Young, Julie N King, et al.
Journal of Medicinal Chemistry
|
October 15, 1993
Synthesis, in vitro binding profile, and autoradiographic analysis of [3H]-cis-3-[(2-methoxybenzyl)amino]-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand
T Rosen, T F Seeger, S McLean, et al.
Journal of Medicinal Chemistry
|
November 1, 1990
Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazole
T Rosen, T F Seeger, S McLean, et al.
Plos One
|
April 16, 2011
A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy
Lynn T Matthews, Janet Giddy, Musie Ghebremichael, et al.
The Annals of Otology, Rhinology, and Laryngology
|
February 11, 2015
Effect of Lidocaine on Swallowing During FEES in Patients With Dysphagia
Meredith B O'Dea, Susan E Langmore, Gintas P Krisciunas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens
Stewart B Fleishman, Hina Khan, Peter Homel, et al.
The Oncologist
|
February 3, 2009
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies
Michael J Guarino, Charles J Schneider, Martha A Hosford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
Matthew H Taylor, Courtney B Betts, Lauren Maloney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N Starodub, Allyson J Ocean, Manish A Shah, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 110) with videos related to
Sort By:
Page
of 11
Multiple Sclerosis and Related Disorders
|
November 23, 2015
Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure
Alicia S Chua, Bonnie I Glanz, Anthony J Guarino, et al.
Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology
|
December 17, 2016
Preliminary Predictors of Initial Attendance, Symptom Burden, and Motor Subtype in a US Functional Neurological Disorders Clinic Population
David L Perez, Sigrid S Young, Julie N King, et al.
Journal of Medicinal Chemistry
|
October 15, 1993
Synthesis, in vitro binding profile, and autoradiographic analysis of [3H]-cis-3-[(2-methoxybenzyl)amino]-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand
T Rosen, T F Seeger, S McLean, et al.
Journal of Medicinal Chemistry
|
November 1, 1990
Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazole
T Rosen, T F Seeger, S McLean, et al.
Plos One
|
April 16, 2011
A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy
Lynn T Matthews, Janet Giddy, Musie Ghebremichael, et al.
The Annals of Otology, Rhinology, and Laryngology
|
February 11, 2015
Effect of Lidocaine on Swallowing During FEES in Patients With Dysphagia
Meredith B O'Dea, Susan E Langmore, Gintas P Krisciunas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens
Stewart B Fleishman, Hina Khan, Peter Homel, et al.
The Oncologist
|
February 3, 2009
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies
Michael J Guarino, Charles J Schneider, Martha A Hosford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
Matthew H Taylor, Courtney B Betts, Lauren Maloney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N Starodub, Allyson J Ocean, Manish A Shah, et al.
Page
of 11